Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Influenza Diagnostic Tests Evaluated

By LabMedica International staff writers
Posted on 05 Sep 2012
Recent outbreaks of influenza have underscored the need to validate the accuracy of rapid influenza diagnostic tests (RIDTs) routinely used in clinical settings

The accuracy of seven commercially available tests have been checked as negative results from RIDTs for influenza A (H3N2v) should not be considered reliable evidence of lack of infection. More...

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) checked the seven RIDTs using seven different H3N2v viral strains. H3N2v viruses can be detected by qualified public health laboratories using the CDC Flu Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Diagnostic Panel for A(H3N2)v (CDC Flu rRT-PCR Dx). Five 10-fold dilutions in physiological saline of each virus grown in Madin-Darby Canine Kidney (MDCK) cells were tested with all of the RIDTs in duplicate.

Tests with BinaxNOW Influenza A&B (Alere; Waltham, MA, USA), Directigen EZ Flu A+B (Becton-Dickinson; Franklin Lakes, NJ, USA), SAS FluAlert A&B (SA Scientific; San Antonio, TX, USA), QuickVue Influenza A+B Test and Sofia Influenza A+B (Quidel; San Diego, CA, USA) were performed according to the procedures in the kit inserts for nasal washes or aspirates. Xpect Flu A&B (Remel; Lenexa, KS, USA) tests were performed according to their procedure for nasal washes and swab specimens transported in liquid media. For the BD Veritor System for Rapid Detection of Flu A+B (Becton Dickinson) test, 100 µL of diluted specimen was added directly to the reagent tube.

Positive and negative controls contained in each RIDT were run before testing the viruses in the study to verify performance of each assay lot, with the exception of FluAlert, which does not provide controls. The CDC reports that only four of the seven RIDTs tested, Directigen, Sofia, Veritor, and Xpect, detected all seven of the H3N2v strains. The BinaxNOW test spotted five of the seven strains, and the QuickVue test found three of the seven. The FluAlert test detected only one of the viral samples in this test.

In this evaluation of seven RIDTs, the ability to detect H3N2v virus varied substantially among the tests. This evaluation emphasizes the fact that a negative RIDT result should not be considered as conclusive evidence of lack of infection with influenza A (H3N2)v. More data are needed on the clinical performance of all RIDTs in detecting H3N2v virus in various respiratory specimens. Results from RIDTs, both positive and negative, always should be interpreted in the broader context of the circulating influenza strains present in the area, level of clinical suspicion, severity of illness, and risk for complications in a patient with suspected infection. The study was published on August 17, 2012, in the journal Morbidity and Mortality Weekly Report (MMWR).

Related Links:
US Centers for Disease Control and Prevention




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.